Armata Pharmaceuticals (ARMP) vs Compass Therapeutics (CMPX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Armata Pharmaceuticals (ARMP) has outperformed Compass Therapeutics (CMPX) over the past year, losing 56.9% versus a loss of 85.9%. Over five years, ARMP leads with a -42.0% price change compared with -78.6% for CMPX. Compass Therapeutics is the larger company by market cap ($123.9 million vs $112.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARMP | CMPX |
|---|---|---|
| Share price | $3.03 | $0.6882 |
| Market cap | $112.69M | $123.94M |
| 1-day change | +1.68% | +1.43% |
| YTD return | -51.75% | -87.18% |
| 1-year return | -56.90% | -85.87% |
| 5-year return | -41.95% | -78.63% |
| EPS (TTM) | $-4.17 | $-0.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-173.80M | $-66.49M |
| 52-week high | $14.98 | $6.88 |
| 52-week low | $2.40 | $0.57 |
| Distance from 52-week high | -79.77% | -90.00% |
| Analyst consensus | none | buy |
| Avg. price target upside | +477.56% | +664.31% |
| Average volume | 182.52K | 3.88M |
| Shares outstanding | 37.19M | 180.09M |
| Employees | 61 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARMP has outperformed CMPX by 29.0 percentage points over the past year.
About Armata Pharmaceuticals
ARMP stock →Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 61 employees
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
ARMP vs CMPX FAQ
Which is bigger, Armata Pharmaceuticals or Compass Therapeutics?
Compass Therapeutics (CMPX) is larger, with a market capitalization of $123.94M compared with $112.69M for Armata Pharmaceuticals (ARMP).
Which stock has performed better over the past year, ARMP or CMPX?
ARMP returned -56.90% over the past 12 months, compared with -85.87% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Armata Pharmaceuticals and Compass Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.